Market Overview

Merck Gets A Strong Sell From Vetr Crowd

Related MRK
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
Merck's Keytruda Gets FDA Priority Review For Rare Lymphoma
Stocks to watch next week (Seeking Alpha)

On Tuesday, the Vetr crowd downgraded their rating for Merck & Co., Inc. (NYSE: MRK) from 2 stars (Sell), issued two weeks ago, to 1.5 stars (Strong Sell). Still, the Vetr crowd remained confident in the stock as 75 percent of user ratings were bullish.

There have been some signs of life in Merck's price over the past couple of days following a bit of a selloff last week where the price dropped nearly $4. Part of this movement could be due to the rollercoaster of news regarding Merck's successful trial of a potential Ebola vaccine.

The stock closed at $59.27.

See how crowdsourced ratings could help you time the market.

Currently, the vetr crowd's average target price for the stock is down at $52.27, well below the average analyst price of $65.20. Less than 2 percent of Vetr users are holding MRK in their watch-lists.

Latest Ratings for MRK

Nov 2017Bank of AmericaReinstatesBuyBuy
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017JefferiesUpgradesUnderperformHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: VetrBiotech Downgrades Crowdsourcing Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!